HMP CommunicationsFDA Approves Novel Dosing Regimen for Cetuximab in CRC, Head and Neck Cancer

The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.

M3This One Pill Could Save Millions of Lives Worldwide

According to the results of a new clinical trial published in The New England Journal of Medicine (NEJM), a simple treatment that combines four heart medicines in one pill—a “polypill”—was able to cut the risk of heart attack, stroke, and other cardiovascular events by 21% in people at risk of heart disease, and by 31% […]

American Society of HematologyASH Annual Meeting: Does High-Dose Methotrexate Protect the CNS in High-Risk DLBCL?

The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.

HMP CommunicationsFirst-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC

In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).